Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer.
Br J Cancer
; 120(5): 522-526, 2019 03.
Article
em En
| MEDLINE
| ID: mdl-30745584
ABSTRACT
BACKGROUND:
HER2 is the only validated predictive biomarker in gastro-oesophageal carcinoma (GOC). However, several factors, such as heterogeneity in protein expression, shortage of evaluable tumour tissue and need for quick target assessment, underline the usefulness of a pre-screening tool in order to anticipate HER2 status.METHODS:
Data from 723 consecutive GOC analysed for HER2 at four Italian Institutions were collected. HER2 positivity was defined as 3+ by immunohistochemistry (IHC) or 2+ with gene amplification by in situ hybridisation (ISH). A multivariate logistic regression model was built using data from 413 cases, whereas 310 patients served as validation cohort. C-index, visual inspection of the calibration plot, Brier score and Spiegelhalter z-test were used to assess the performance of the nomogram.RESULTS:
HER2 positive rate was 17.4%. Four variables were retained after adjustment in the final model grading, Lauren's histotype, pathologic material analysed (surgical specimen/biopsy) and site of tissue collection (primary tumour/metastases). Visual inspection of the calibration plot revealed a very good overlap between predicted and observed probabilities, with a Brier score of 0.101 and a non-significant Spiegelhalter z-test (P = 0.319). C-index resulted in 0.827 (95%CI 0.741-0.913).CONCLUSION:
A simple nomogram based on always-available pathologic information accurately predicts the probability of HER2 positivity in GOC.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Gástricas
/
Carcinoma
/
Receptor ErbB-2
/
Junção Esofagogástrica
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article